Literature DB >> 15939869

Robust hepatitis C virus infection in vitro.

Jin Zhong1, Pablo Gastaminza, Guofeng Cheng, Sharookh Kapadia, Takanobu Kato, Dennis R Burton, Stefan F Wieland, Susan L Uprichard, Takaji Wakita, Francis V Chisari.   

Abstract

The absence of a robust cell culture model of hepatitis C virus (HCV) infection has severely limited analysis of the HCV life cycle and the development of effective antivirals and vaccines. Here we report the establishment of a simple yet robust HCV cell culture infection system based on the HCV JFH-1 molecular clone and Huh-7-derived cell lines that allows the production of virus that can be efficiently propagated in tissue culture. This system provides a powerful tool for the analysis of host-virus interactions that should facilitate the discovery of antiviral drugs and vaccines for this important human pathogen.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15939869      PMCID： PMC1166622          DOI： 10.1073/pnas.0503596102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  50 in total

1.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

2.  CD81 is required for hepatitis C virus glycoprotein-mediated viral infection.

Authors:  Jie Zhang; Glenn Randall; Adrian Higginbottom; Peter Monk; Charles M Rice; Jane A McKeating
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease.

Authors:  Robert Thimme; Jens Bukh; Hans Christian Spangenberg; Stefan Wieland; Janell Pemberton; Carola Steiger; Sugantha Govindarajan; Robert H Purcell; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-19       Impact factor: 11.205

4.  The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.

Authors:  Mitsutoshi Yoneyama; Mika Kikuchi; Takashi Natsukawa; Noriaki Shinobu; Tadaatsu Imaizumi; Makoto Miyagishi; Kazunari Taira; Shizuo Akira; Takashi Fujita
Journal:  Nat Immunol       Date:  2004-06-20       Impact factor: 25.606

Review 5.  What is disrupting IFN-alpha's antiviral activity?

Authors:  M Lamine Mbow; Robert T Sarisky
Journal:  Trends Biotechnol       Date:  2004-08       Impact factor: 19.536

6.  Neutralizing antibody response during acute and chronic hepatitis C virus infection.

Authors:  C Logvinoff; M E Major; D Oldach; S Heyward; A Talal; P Balfe; S M Feinstone; H Alter; C M Rice; J A McKeating
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-25       Impact factor: 11.205

7.  Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells.

Authors:  Tomoko Date; Takanobu Kato; Michiko Miyamoto; Zijiang Zhao; Kotaro Yasui; Masashi Mizokami; Takaji Wakita
Journal:  J Biol Chem       Date:  2004-02-26       Impact factor: 5.157

Review 8.  A critical role for the chimpanzee model in the study of hepatitis C.

Authors:  Jens Bukh
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

9.  CD81 is an entry coreceptor for hepatitis C virus.

Authors:  Emmanuel G Cormier; Fay Tsamis; Francis Kajumo; Robert J Durso; Jason P Gardner; Tatjana Dragic
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-03       Impact factor: 11.205

10.  Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes.

Authors:  Darius Moradpour; Matthew J Evans; Rainer Gosert; Zhenghong Yuan; Hubert E Blum; Stephen P Goff; Brett D Lindenbach; Charles M Rice
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103
View more
  798 in total

1.  Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept.

Authors:  C Leboeuf; J Roser-Schilder; M Lambotin; S Durand; T Wu; C Fauvelle; B Su; E Bôle-Richard; M Deschamps; C Ferrand; P Tiberghien; P Pessaux; T F Baumert; E Robinet
Journal:  Gene Ther       Date:  2014-11-13       Impact factor: 5.250

2.  Activity-based protein profiling identifies a host enzyme, carboxylesterase 1, which is differentially active during hepatitis C virus replication.

Authors:  David R Blais; Rodney K Lyn; Michael A Joyce; Yanouchka Rouleau; Rineke Steenbergen; Nicola Barsby; Lin-Fu Zhu; Adrian F Pegoraro; Albert Stolow; David L Tyrrell; John Paul Pezacki
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

3.  Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells.

Authors:  Joo Chun Yoon; Jong-Baeck Lim; Jeon Han Park; Jae Myun Lee
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

Review 4.  A guide to viral inclusions, membrane rearrangements, factories, and viroplasm produced during virus replication.

Authors:  Christopher Netherton; Katy Moffat; Elizabeth Brooks; Thomas Wileman
Journal:  Adv Virus Res       Date:  2007       Impact factor: 9.937

5.  In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.

Authors:  Tse-I Lin; Oliver Lenz; Gregory Fanning; Thierry Verbinnen; Frédéric Delouvroy; Annick Scholliers; Katrien Vermeiren; Asa Rosenquist; Michael Edlund; Bertil Samuelsson; Lotta Vrang; Herman de Kock; Piet Wigerinck; Pierre Raboisson; Kenneth Simmen
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

6.  Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.

Authors:  Yueh-Ming Loo; David M Owen; Kui Li; Andrea K Erickson; Cynthia L Johnson; Penny M Fish; D Spencer Carney; Ting Wang; Hisashi Ishida; Mitsutoshi Yoneyama; Takashi Fujita; Takeshi Saito; William M Lee; Curt H Hagedorn; Daryl T-Y Lau; Steven A Weinman; Stanley M Lemon; Michael Gale
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-03       Impact factor: 11.205

7.  Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame.

Authors:  Weiliang Tang; Catherine A Lázaro; Jean S Campbell; W Tony Parks; Michael G Katze; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

8.  Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.

Authors:  Thomas Pietschmann; Artur Kaul; George Koutsoudakis; Anna Shavinskaya; Stephanie Kallis; Eike Steinmann; Karim Abid; Francesco Negro; Marlene Dreux; Francois-Loic Cosset; Ralf Bartenschlager
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

9.  Limited hepatitis B virus replication space in the chronically hepatitis C virus-infected liver.

Authors:  S F Wieland; S Asabe; R E Engle; R H Purcell; F V Chisari
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

10.  Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis.

Authors:  Brian Webster; Silke Wissing; Eva Herker; Melanie Ott; Warner C Greene
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.